All News about Editas Medicine![]() ![]() ![]() ![]() ![]() ![]() ![]()
Expert Ratings for Editas Medicine
February 01, 2023
Via Benzinga
![]() ![]()
Analyst Expectations for Editas Medicine's Future
January 10, 2023
Via Benzinga
![]()
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
February 01, 2023
Via Benzinga
![]()
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
Via Benzinga
![]() ![]()
Analyst Ratings for Editas Medicine
December 06, 2022
Via Benzinga
![]() ![]() ![]() ![]() ![]() Via GlobeNewswire
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
Via Benzinga
![]()
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
November 18, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|
Editas Medicine (NQ: EDIT )All News about Editas Medicine
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|